Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Acquisitions (2020 - 2024)

Haemonetics has reported Acquisitions over the past 9 years, most recently at $1.8 million for Q3 2024.

  • Quarterly results put Acquisitions at $1.8 million for Q3 2024, changed N/A from a year ago — trailing twelve months through Jun 2025 was $1.8 million (down 99.55% YoY), and the annual figure for FY2025 was $150.9 million, down 38.12%.
  • Acquisitions for Q3 2024 was $1.8 million at Haemonetics, down from $149.2 million in the prior quarter.
  • Over the last five years, Acquisitions for HAE hit a ceiling of $418.2 million in Q2 2021 and a floor of $1.8 million in Q3 2024.
  • Median Acquisitions over the past 5 years was $16.6 million (2020), compared with a mean of $119.3 million.
  • Biggest five-year swings in Acquisitions: plummeted 84.95% in 2021 and later grew 14.0% in 2022.
  • Haemonetics' Acquisitions stood at $16.6 million in 2020, then plummeted by 84.95% to $2.5 million in 2021, then increased by 14.0% to $2.8 million in 2022, then skyrocketed by 8456.21% to $243.9 million in 2023, then crashed by 99.28% to $1.8 million in 2024.
  • The last three reported values for Acquisitions were $1.8 million (Q3 2024), $149.2 million (Q2 2024), and $243.9 million (Q4 2023) per Business Quant data.